Blue Water Vaccines is a biopharmaceutical company developing transformational vaccines targeting major global health challenges. Headquartered in Cincinnati, OH, the company holds rights to proprietary technology from the University of Oxford, Cincinnati Children’s Hospital Medical Center, and St. Jude Children’s Hospital. Its pipeline includes a universal flu vaccine candidate, a licensed norovirus S&P nanoparticle VLP platform to develop vaccines for norovirus/rotavirus and malaria, and a Streptococcus pneumoniae candidate aimed at preventing pediatric acute otitis media. The company intends to advance these programs through continued research and development and licensing where applicable. Blue Water Vaccines disclosed use of transaction proceeds for R&D of its pipeline as well as working capital and other general corporate purposes. The press release frames these efforts within ongoing development and financing needs typical of clinical-stage vaccine developers. Blue Water Vaccines is developing a single vaccine intended to protect against all influenza strains, using technology and mathematical models developed at the University of Oxford. Preclinical work, including mouse studies, found that vaccinating with four variants of a region of limited variability produced immunity to historical influenza strains. The company secured exclusive rights to the vaccine from Oxford University Innovation. Blue Water Vaccines closed a $7 million oversubscribed seed capital round led by CincyTech, with participation from CincyTech-affiliated private investors. The financing will fund an additional preclinical study and support a Phase 1 trial targeted for 2020. The company will be headquartered in Cincinnati, Ohio, with a lab in Oxford, UK, and is led by CEO Joseph Hernandez.

Total raised

$15M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2022